期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 9, 期 400, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aal1645
关键词
-
资金
- Basser Center for BRCA
- Harry Fields Professorship
- NIH [R01CA142776, R01CA190415, P50CA083638, P50CA174523, R01CA148759, R21CA198558, U01CA200495, R01NS094533]
- Breast Cancer Alliance
- Ovarian Cancer Research Fund
- Foundation for Women's Cancer
- Kaleidoscope of Hope Ovarian Cancer Foundation
- Marsha Rivkin Center for Ovarian Cancer Research
- China Scholarship Council
Strategies to enhance response to poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)-proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized epigenetic drugs and identified bromodomain and extraterminal domain inhibitors (BETis; JQ1, I-BET762, and OTX015) as drugs that acted synergistically with olaparib in HR-proficient cancer cells. Functional assays demonstrated that repressed BET activity reduces HR and thus enhances PARPi-induced DNA damage in cancer cells. We also found that inhibition or depletion of BET proteins impairs transcription of BRCA1 and RAD51, two genes essential for HR. Moreover, BETi treatment sensitized tumors to PARP inhibition in preclinical animal models of HR-proficient breast and ovarian cancers. Finally, we showed that the BRD4 gene was focally amplified across 20 types of common cancers. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据